<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9710149" created="22/06/2006" creator="Noriko Katsu"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>9710149</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term id="T1" lex="Dimethyldithiocarbamate" sem="Organic_compound_other">Dimethyldithiocarbamate</term> inhibits in vitro activation of <term id="T2" lex="primary_human_CD4+_T_lymphocyte" sem="Cell_natural">primary human CD4+ T lymphocytes</term>.</sentence>
<event id="E1">
<type class="Negative_regulation"/>
<theme idref="E2"/>
<cause idref="T1"/>
<clue>Dimethyldithiocarbamate <clueType>inhibits</clueType> in vitro activation of primary human CD4+ T lymphocytes.</clue>
</event>
<event KT="Other" id="E2">
<type class="Physiological_process"/>
<theme idref="T2"/>
<clue>Dimethyldithiocarbamate inhibits in vitro <clueType>activation</clueType> <linkTheme>of</linkTheme> primary human CD4+ T lymphocytes.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2"><term id="T3" lex="dithiocarbamate" sem="Organic_compound_other">Dithiocarbamates</term> (<term id="T4" lex="DTC" sem="Organic_compound_other">DTC</term>), a diverse group of industrial and <term id="T5" lex="therapeutic_chemical" sem="Organic_compound_other">therapeutic chemicals</term>, have been reported to inhibit, enhance or have no effect on the <term id="T6" lex="immune_system" sem="Other">immune system</term>.</sentence>
<event KT="Analysis" id="E3">
<type class="Negative_regulation"/>
<theme idref="T6"/>
<cause idref="T4"/>
<clue>Dithiocarbamates (DTC), a diverse group of industrial and therapeutic chemicals, have been <clueKT>reported</clueKT> to <clueType>inhibit</clueType>, enhance or have no effect <linkTheme>on</linkTheme> the immune system.</clue>
</event>
<event KT="Analysis" id="E24">
<type class="Positive_regulation"/>
<theme idref="T6"/>
<cause idref="T4"/>
<clue>Dithiocarbamates (DTC), a diverse group of industrial and therapeutic chemicals, have been <clueKT>reported</clueKT> to inhibit, <clueType>enhance</clueType> or have no effect <linkTheme>on</linkTheme> the immune system.</clue>
</event>
<event KT="Analysis" Polarity="Negative" assertion="non-exist" id="E25">
<type class="Regulation"/>
<theme idref="T6"/>
<cause idref="T4"/>
<clue>Dithiocarbamates (DTC), a diverse group of industrial and therapeutic chemicals, have been <clueKT>reported</clueKT> to inhibit, enhance or have <cluePolarity>no</cluePolarity> <clueType>effect</clueType> <linkTheme>on</linkTheme> the immune system.</clue>
</event>
<sentence id="S3">These apparent inconsistencies reflect the complexity of the <term id="T70" sem="Other"><term id="T7" lex="DTC" sem="Organic_compound_other">DTCs</term> biological activities</term> and are probably due in part to differences in dose, route of exposure, animal species used and/or specific compound tested.</sentence>
<sentence id="S4">The studies described herein were undertaken to investigate the <term id="T9" lex="immunotoxicity" sem="Other">immunotoxicity</term> of one member of this family, <term id="T10" lex="dimethyldithiocarbamate" sem="Organic_compound_other">dimethyldithiocarbamate</term> (<term id="T11" lex="DMDTC" sem="Organic_compound_other">DMDTC</term>).</sentence>
<sentence id="S5">We demonstrate that 0.1-0.5 microM <term id="T12" lex="DMDTC" sem="Organic_compound_other">DMDTC</term> inhibits <term id="T14" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term>-induced <term id="T13" sem="Other">activation</term> of <term id="T15" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> in <term id="T16" lex="primary_human_CD4+_T_cell" sem="Cell_natural">primary human CD4+ T cells</term>.</sentence>
<event KT="Analysis" id="E5">
<type class="Negative_regulation"/>
<theme idref="E6"/>
<cause idref="T12"/>
<clue>We <clueKT>demonstrate</clueKT> that 0.1-0.5 microM DMDTC <clueType>inhibits</clueType> TNF-alpha-induced activation of NF-kappaB in primary human CD4+ T cells.</clue>
</event>
<event KT="Other" id="E6">
<type class="Positive_regulation"/>
<theme idref="T15"/>
<cause idref="T14"/>
<clue>We demonstrate that 0.1-0.5 microM DMDTC inhibits TNF-alpha<linkCause>-induced</linkCause> <clueType>activation</clueType> <linkTheme>of</linkTheme> NF-kappaB <clueLoc>in primary human CD4+ T cells</clueLoc>.</clue>
</event>
<sentence id="S6">This inhibition is not accompanied by a loss in <term id="A1" sem="Other">viability</term>, and <term id="T17" lex="DMDTC-treated_T_cell" sem="Cell_natural"><term id="T18" lex="DMDTC" sem="Organic_compound_other">DMDTC</term>-treated <term id="A3" sem="Cell_natural">T cells</term></term> retain other active <term id="A2" sem="Other">signaling pathways</term> throughout the exposure duration.</sentence>
<event Polarity="Negative" assertion="non-exist" id="E7">
<type class="Negative_regulation"/>
<theme idref="A1"/>
<cause idref="E5"/>
<clue><corefTheme>This inhibition</corefTheme> is <cluePolarity>not</cluePolarity> <clueType>accompanied by a loss</clueType> <linkTheme>in</linkTheme> viability, and DMDTC-treated T cells retain other active signaling pathways throughout the exposure duration.</clue>
</event>
<event id="E8">
<type class="Positive_regulation"/>
<theme idref="A2"/>
<clue>This inhibition is not accompanied by a loss in viability, and <clueLoc>DMDTC-treated T cells</clueLoc> <clueType>retain</clueType> other <clueType>active</clueType> signaling pathways <clueTime>throughout the exposure duration</clueTime>.</clue>
</event>
<event KT="Method" id="E9">
<type class="Artificial_process"/>
<theme idref="T18"/>
<theme idref="A3"/>
<clue>This inhibition is not accompanied by a loss in viability, and DMDTC-<clueType>treated</clueType> T cells retain other active signaling pathways throughout the exposure duration.</clue>
</event>
<sentence id="S7">The inhibition of <term id="T20" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> is apparently permanent as <term id="T21" lex="DMDTC-treated_T_cell" sem="Cell_natural"><term id="T22" lex="DMDTC" sem="Organic_compound_other">DMDTC</term>-treated <term id="A4" sem="Cell_natural">T cells</term></term> did not regain normal <term id="T23" lex="TNF-alpha_activation" sem="Other"><term id="T24" lex="TNF-alpha" sem="Protein_molecule">TNF-alpha</term> activation</term>, even after 72 h in culture.</sentence>
<event CL="L2" KT="Analysis" id="E10">
<type class="Negative_regulation"/>
<theme idref="T20"/>
<clue>The <clueType>inhibition</clueType> <linkTheme>of</linkTheme> NF-kappaB is <clueKT><clueCL>apparently</clueCL></clueKT> permanent as DMDTC-treated T cells did not regain normal TNF-alpha activation, even after 72 h in culture.</clue>
</event>
<event KT="Other" id="E11">
<type class="Positive_regulation"/>
<theme idref="T24"/>
<clue>The inhibition of NF-kappaB is apparently permanent as DMDTC-treated T cells did not regain normal TNF-alpha <clueType>activation</clueType>, even after 72 h in culture.</clue>
</event>
<event Polarity="Negative" assertion="non-exist" id="E12">
<type class="Positive_regulation"/>
<theme idref="E11"/>
<cause idref="E13"/>
<clue>The inhibition of NF-kappaB is apparently permanent as <clueLoc>DMDTC-treated T cells</clueLoc> did <cluePolarity>not</cluePolarity> <clueType>regain</clueType> normal TNF-alpha activation, even <clueTime>after 72 h in culture</clueTime>.</clue>
</event>
<event KT="Method" id="E13">
<type class="Artificial_process"/>
<theme idref="A4"/>
<theme idref="T22"/>
<clue>The inhibition of NF-kappaB is apparently permanent as DMDTC-<clueType>treated</clueType> T cells did not regain normal TNF-alpha activation, even after 72 h in culture.</clue>
</event>
<sentence id="S8"><term id="T25" lex="DMDTC" sem="Organic_compound_other">DMDTC</term> does not appear to alter <term id="T26" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> directly as pre-incubation of <term id="A5" sem="Cell_component">nuclear extracts</term> with <term id="T27" lex="DMDTC" sem="Organic_compound_other">DMDTC</term> does not diminish binding activity of this protein.</sentence>
<event CL="L2" KT="Analysis" Polarity="Negative" assertion="non-exist" id="E14" uncertainty="probable">
<type class="Regulation"/>
<theme idref="T26"/>
<cause idref="T25"/>
<clue>DMDTC does <cluePolarity>not</cluePolarity> <clueKT><clueCL>appear</clueCL></clueKT> to <clueType>alter</clueType> NF-kappaB directly as pre-incubation of nuclear extracts with DMDTC does not diminish binding activity of this protein.</clue>
</event>
<event KT="Method" id="E15">
<type class="Artificial_process"/>
<theme idref="A5"/>
<theme idref="T27"/>
<clue>DMDTC does not appear to alter NF-kappaB directly as <clueTime>pre</clueTime>-<clueType>incubation</clueType> <linkTheme>of</linkTheme> nuclear extracts <linkTheme>with</linkTheme> DMDTC does not diminish binding activity of this protein.</clue>
</event>
<event Polarity="Negative" assertion="non-exist" id="E16">
<type class="Negative_regulation"/>
<theme idref="E17"/>
<cause idref="E15"/>
<clue>DMDTC does not appear to alter NF-kappaB directly as pre-incubation of nuclear extracts with DMDTC does <cluePolarity>not</cluePolarity> <clueType>diminish</clueType> binding activity of this protein.</clue>
</event>
<event id="E17">
<type class="Binding"/>
<theme idref="T26"/>
<clue>DMDTC does not appear to alter NF-kappaB directly as pre-incubation of nuclear extracts with DMDTC does not diminish <clueType>binding activity</clueType> <linkTheme>of</linkTheme> <corefTheme>this protein</corefTheme>.</clue>
</event>
<sentence id="S9">We further demonstrate that 0.1-0.5 microM <term id="T28" lex="DMDTC" sem="Organic_compound_other">DMDTC</term> inhibits intracellular <term id="T19" sem="Other"><term id="T30" lex="IL-2" sem="Protein_molecule">IL-2</term> production</term> and decreases surface expression of <term id="T31" lex="CD25" sem="Protein_molecule">CD25</term> (the <term id="T32" lex="alpha_subunit" sem="Protein_molecule">alpha subunit</term> of the <term id="T33" lex="IL-2_receptor" sem="Protein_complex"><term id="T34" lex="IL-2" sem="Protein_molecule">IL-2</term> receptor</term>) in <term id="T35" lex="T_cell" sem="Cell_natural">T cells</term> stimulated with <term id="T36" lex="phorbol_ester" sem="Organic_compound_other">phorbol ester</term>.</sentence>
<event KT="Analysis" id="E18">
<type class="Negative_regulation"/>
<theme idref="E19"/>
<cause idref="T28"/>
<clue>We further <clueKT>demonstrate</clueKT> that 0.1-0.5 microM DMDTC <clueType>inhibits</clueType> intracellular IL-2 production and decreases surface expression of CD25 (the alpha subunit of the IL-2 receptor) <clueLoc>in T cells stimulated with phorbol ester</clueLoc>.</clue>
</event>
<event KT="Other" id="E19">
<type class="Gene_expression"/>
<theme idref="T30"/>
<clue>We further demonstrate that 0.1-0.5 microM DMDTC inhibits <clueLoc>intracellular</clueLoc> IL-2 <clueType>production</clueType> and decreases surface expression of CD25 (the alpha subunit of the IL-2 receptor) in T cells stimulated with phorbol ester.</clue>
</event>
<event KT="Analysis" id="E20">
<type class="Negative_regulation"/>
<theme idref="E21"/>
<cause idref="T28"/>
<clue>We further <clueKT>demonstrate</clueKT> that 0.1-0.5 microM DMDTC inhibits intracellular IL-2 production and <clueType>decreases</clueType> surface expression of CD25 (the alpha subunit of the IL-2 receptor) <clueLoc>in T cells stimulated with phorbol ester</clueLoc>.</clue>
</event>
<event id="E21">
<type class="Gene_expression"/>
<theme idref="T31"/>
<clue>We further demonstrate that 0.1-0.5 microM DMDTC inhibits intracellular IL-2 production and decreases <clueLoc>surface</clueLoc> <clueType>expression</clueType> <linkTheme>of</linkTheme> CD25 (the alpha subunit of the IL-2 receptor) in T cells stimulated with phorbol ester.</clue>
</event>
<event id="E22">
<type class="Physiological_process"/>
<theme idref="T35"/>
<cause idref="T36"/>
<clue>We further demonstrate that 0.1-0.5 microM DMDTC inhibits intracellular IL-2 production and decreases surface expression of CD25 (the alpha subunit of the IL-2 receptor) in T cells <clueType>stimulated</clueType> <linkCause>with</linkCause> phorbol ester.</clue>
</event>
<sentence id="S10">These data demonstrate that <term id="T37" lex="DMDTC" sem="Organic_compound_other">DMDTC</term> is a potent <term id="T38" lex="immunosuppressive_compound" sem="Organic_compound_other">immunosuppressive compound</term> in vitro.</sentence>
<event KT="Analysis" Manner="High" id="E23">
<type class="Negative_regulation"/>
<cause idref="T37"/>
<clue>These data <clueKT>demonstrate</clueKT> that DMDTC is a <clueManner>potent</clueManner> <clueType>immunosuppressive</clueType> compound in vitro.</clue>
<comment>NO THEME</comment></event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
